At ASH 2025, major findings from the PARADIGM trial showed azacitidine (Aza) + venetoclax (Ven) significantly improved event-free survival (EFS), response rates, and tolerability compared to standard intensive chemo for fit, newly diagnosed AML patients, potentially offering a safer, superior frontline option. In the trial, 172 adult patients were randomly assigned to receive either aza-ven or standard intensive … Read more

For most, but not all cancers detecting them early improves outcome. This article in the Telegraph 17 June 2025 explains what signs and symptoms to check for https://www.telegraph.co.uk/health-fitness/conditions/cancer/cancer-signs-to-check-for

Breaking News from 18th International Malignant Lymphoma Meeting, Lugano June 2025 POLARGO Trial Shows Overall Survival Benefit with Pola-R-GemOx in Transplant-Ineligible R/R DLBCL The POLARGO trial (NCT04182204) is a global, randomized, Phase III study designed to evaluate the efficacy and safety of polatuzumab vedotin in combination with rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) versus rituximab, gemcitabine, … Read more

On 2 April 2025 NICE approved brentuxtimab vedotin for new diagnosed patients with stage 3 or 4 Hodgkin lymphoma. Brentuximab will be given in combination with 3 chemotherapy drugs – doxorubicin, dacarbazine and vinblastine. This is excellent news and another treatment option for patients with advanced Hodgkin lymphoma.

High-risk smouldering myeloma The Aquila Study randomised 390 patients with high-risk smouldering myeloma to receive either sub-cutaneous daratumumab every 28 days or active monitoring for up to 36 months or until their condition progressed to myeloma. High-risk myeloma was defined as patients with features that had them at more than 50% of developing myeloma within … Read more

Myeloma – The DREAMM-8 clinical trial that was presented at ASCO and published in the NEJM in June 2024 was a randomised trial comparing belantamab mafodotin, pomalidomide and dexamethasone (BPd) with pomalidomide, bortezomib and dexamethasone (PVd) in lenalidomide-exposed patients who had relapsed/refractory disease after at least one line of treatment. Patients randomised to BPd had … Read more

Myeloma – the phase 3 PERSEUS trial from the European Myeloma Network randomised approximately 700 newly diagnosed patients with myeloma to treatment with dartumumab, velcade, revlimid and dexamethasone (D-VRD) or VRD followed by an autologous stem cell transplantation, 2 cycles of consolidation with D-VRD or VRD followed by maintenance treatment with dara-revlimid or revlimid alone. … Read more